DK4073098T3 - Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse - Google Patents
Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK4073098T3 DK4073098T3 DK20830444.4T DK20830444T DK4073098T3 DK 4073098 T3 DK4073098 T3 DK 4073098T3 DK 20830444 T DK20830444 T DK 20830444T DK 4073098 T3 DK4073098 T3 DK 4073098T3
- Authority
- DK
- Denmark
- Prior art keywords
- ultra
- methods
- long
- fusion proteins
- acting insulin
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950803P | 2019-12-19 | 2019-12-19 | |
| US202062988441P | 2020-03-12 | 2020-03-12 | |
| PCT/US2020/063673 WO2021126584A1 (en) | 2019-12-19 | 2020-12-07 | Ultra-long acting insulin-fc fusion proteins and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK4073098T3 true DK4073098T3 (da) | 2023-11-20 |
| DK4073098T5 DK4073098T5 (da) | 2024-07-22 |
Family
ID=74104207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20830444.4T DK4073098T5 (da) | 2019-12-19 | 2020-12-07 | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11352407B2 (da) |
| EP (2) | EP4073098B1 (da) |
| JP (1) | JP7405486B2 (da) |
| KR (1) | KR20220115975A (da) |
| CN (1) | CN114846025A (da) |
| AU (1) | AU2020407365B2 (da) |
| BR (1) | BR112022012071A2 (da) |
| CA (1) | CA3159486A1 (da) |
| DK (1) | DK4073098T5 (da) |
| FI (1) | FI4073098T3 (da) |
| HR (1) | HRP20231433T1 (da) |
| HU (1) | HUE064376T2 (da) |
| IL (1) | IL294051A (da) |
| LT (1) | LT4073098T (da) |
| SI (1) | SI4073098T1 (da) |
| WO (1) | WO2021126584A1 (da) |
| ZA (1) | ZA202206047B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3892628B1 (en) | 2018-06-29 | 2022-09-07 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| HRP20230990T1 (hr) | 2020-04-10 | 2023-12-08 | Akston Biosciences Corporation | Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| EP4373861A2 (en) | 2021-07-23 | 2024-05-29 | Akston Biosciences Corporation | Insulin-fc fusion proteins and methods of use to treat cancer |
| AR127619A1 (es) | 2021-11-15 | 2024-02-14 | Lilly Co Eli | FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030040601A1 (en) | 2001-06-08 | 2003-02-27 | Ivan Diers | Method for making insulin precursors and insulin analog precursors |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US8569231B2 (en) | 2009-03-20 | 2013-10-29 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| CA2754408A1 (en) | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| EP2598170A4 (en) | 2010-07-28 | 2016-07-06 | Smartcells Inc | MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES |
| JP2013535467A (ja) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| AR087433A1 (es) | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| WO2013074598A1 (en) | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| LT2804623T (lt) | 2012-01-12 | 2019-12-10 | Bioverativ Therapeutics Inc | Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas |
| EP3616727B1 (en) | 2013-02-26 | 2021-03-31 | Hanmi Pharm. Co., Ltd. | Insulin analog conjugates and use thereof |
| CA2913155A1 (en) * | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
| EP3194429A4 (en) | 2014-09-18 | 2018-06-13 | Askgene Pharma, Inc. | Novel feline erythropoietin receptor agonists |
| WO2016105545A2 (en) | 2014-12-24 | 2016-06-30 | Case Western Reserve University | Insulin analogues with enhanced stabilized and reduced mitogenicity |
| EP3250589A4 (en) | 2015-01-29 | 2018-06-20 | Nexvet Australia Pty Ltd | Therapeutic and diagnostic agents |
| JP2018508504A (ja) | 2015-02-17 | 2018-03-29 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続型インスリンまたはインスリンアナログ結合体 |
| CN107709355B (zh) | 2015-05-04 | 2021-09-14 | 阿珀吉尼科斯股份公司 | 单链cd40受体激动剂蛋白 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| CN107743494B (zh) | 2015-06-02 | 2022-04-29 | 诺和诺德股份有限公司 | 具有极性重组延伸体的胰岛素 |
| EP3913000A1 (en) * | 2015-10-02 | 2021-11-24 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| EP3757119A1 (en) | 2015-11-16 | 2020-12-30 | Ubiprotein, Corp. | A method for extending half-life of a protein |
| EP3481413A4 (en) | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| BR112019005637A2 (pt) | 2016-09-23 | 2019-07-30 | Hanmi Pharm Ind Co Ltd | análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| HUE055417T2 (hu) | 2016-12-09 | 2021-11-29 | Akston Biosciences Corp | Inzulin-Fc fúziók és alkalmazási eljárások |
| AR111122A1 (es) | 2017-03-07 | 2019-06-05 | Univ Case Western Reserve | Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| WO2019204206A1 (en) | 2018-04-16 | 2019-10-24 | Chou Danny Hung Chieh | Glucose-responsive insulin |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP3892628B1 (en) | 2018-06-29 | 2022-09-07 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| CA3114395A1 (en) | 2018-09-25 | 2020-04-02 | Absci, Llc | Protein purification methods |
| AR116605A1 (es) | 2018-10-05 | 2021-05-26 | Novo Nordisk As | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) |
| US20220002373A1 (en) | 2018-11-19 | 2022-01-06 | Case Western Reserve University | Single-chain insulin analogues with poly-alanine c-domain sub-segments |
| WO2020236762A2 (en) | 2019-05-17 | 2020-11-26 | Case Western Reserve University | Variant single-chain insulin analogues |
| WO2021011827A1 (en) | 2019-07-16 | 2021-01-21 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
-
2020
- 2020-12-07 FI FIEP20830444.4T patent/FI4073098T3/fi active
- 2020-12-07 US US17/114,395 patent/US11352407B2/en active Active
- 2020-12-07 EP EP20830444.4A patent/EP4073098B1/en active Active
- 2020-12-07 DK DK20830444.4T patent/DK4073098T5/da active
- 2020-12-07 JP JP2022536936A patent/JP7405486B2/ja active Active
- 2020-12-07 LT LTEPPCT/US2020/063673T patent/LT4073098T/lt unknown
- 2020-12-07 HR HRP20231433TT patent/HRP20231433T1/hr unknown
- 2020-12-07 KR KR1020227022527A patent/KR20220115975A/ko unknown
- 2020-12-07 SI SI202030309T patent/SI4073098T1/sl unknown
- 2020-12-07 IL IL294051A patent/IL294051A/en unknown
- 2020-12-07 BR BR112022012071A patent/BR112022012071A2/pt unknown
- 2020-12-07 CN CN202080088372.8A patent/CN114846025A/zh active Pending
- 2020-12-07 EP EP23198760.3A patent/EP4282473A3/en active Pending
- 2020-12-07 WO PCT/US2020/063673 patent/WO2021126584A1/en active Application Filing
- 2020-12-07 CA CA3159486A patent/CA3159486A1/en active Pending
- 2020-12-07 AU AU2020407365A patent/AU2020407365B2/en active Active
- 2020-12-07 HU HUE20830444A patent/HUE064376T2/hu unknown
-
2021
- 2021-11-19 US US17/531,033 patent/US11555058B2/en active Active
-
2022
- 2022-05-31 ZA ZA2022/06047A patent/ZA202206047B/en unknown
-
2023
- 2023-01-10 US US18/152,595 patent/US20230250148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| LT4073098T (lt) | 2023-12-11 |
| CN114846025A (zh) | 2022-08-02 |
| JP7405486B2 (ja) | 2023-12-26 |
| EP4282473A2 (en) | 2023-11-29 |
| US20210309709A1 (en) | 2021-10-07 |
| EP4282473A3 (en) | 2024-02-21 |
| IL294051A (en) | 2022-08-01 |
| CA3159486A1 (en) | 2021-06-24 |
| KR20220115975A (ko) | 2022-08-19 |
| EP4073098A1 (en) | 2022-10-19 |
| AU2020407365A1 (en) | 2022-06-09 |
| WO2021126584A1 (en) | 2021-06-24 |
| EP4073098B1 (en) | 2023-09-27 |
| US20230250148A1 (en) | 2023-08-10 |
| HUE064376T2 (hu) | 2024-03-28 |
| US11555058B2 (en) | 2023-01-17 |
| FI4073098T3 (fi) | 2023-11-15 |
| JP2023507376A (ja) | 2023-02-22 |
| HRP20231433T1 (hr) | 2024-03-29 |
| AU2020407365B2 (en) | 2023-09-21 |
| US11352407B2 (en) | 2022-06-07 |
| BR112022012071A2 (pt) | 2022-08-30 |
| DK4073098T5 (da) | 2024-07-22 |
| US20220064251A1 (en) | 2022-03-03 |
| ZA202206047B (en) | 2023-08-30 |
| SI4073098T1 (sl) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4186920T3 (da) | Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| IL288373A (en) | flt3l-fc fusion proteins and methods of use | |
| DK3565579T3 (da) | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf | |
| DK4073098T5 (da) | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse | |
| DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3601358T3 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3761980T3 (da) | Aminosyreforbindelser og fremgangsmåder til anvendelse | |
| DK3788044T3 (da) | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf | |
| DK3660045T3 (da) | Polypeptid, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3565828T3 (da) | Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf | |
| DK3966207T3 (da) | Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3966206T3 (da) | Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf | |
| DK3794024T3 (da) | Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf | |
| DK3618928T5 (da) | Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| SG11202013170RA (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
| DK3177307T3 (da) | Interleukin-2/interleukin-2 receptor-alpha-fusionsproteiner og fremgangsmåder til anvendelse | |
| IL275742A (en) | IL-22 FC fusion proteins and methods of use | |
| DK3972987T5 (da) | Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf | |
| DK3250610T3 (da) | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf | |
| DK3491025T3 (da) | Fcrn-antistoffer og anvendelsesmetoder heraf | |
| DK3743447T3 (da) | B7-H4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3830120T3 (da) | Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1 | |
| DK3615066T5 (da) | Formuleringer af humane anti-rankl-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3431507T3 (da) | Fusionsprotein omfattende nervevækstfaktor og fremstillingsfremgangsmåde og anvendelse deraf | |
| DK3983064T3 (da) | COT-modulatorer og fremgangsmåder til anvendelse deraf |